A single low dose of dendritic cells modified with lentivirus containing a truncated neu gene can effectively suppress neu-overexpressing tumors.
J Gene Med
; 12(7): 604-12, 2010 Jul.
Article
em En
| MEDLINE
| ID: mdl-20533530
BACKGROUND: Several types of viral-transduced HER2/neu-modified dendritic cells (DC(HER2/neu)) have been used for preventing and/or treating HER2/neu-overexpressing tumors. However, to date, lentivirus has not been used to generate HER2/neu-modified DCs. METHODS: In the present study, we used recombinant lentivirus containing a truncated neu gene (rLVneu) to transduce murine bone marrow-derived dendritic cells and investigated their preventive and therapeutic effects on HER2/neu-overexpressing tumors. RESULTS: The data obtained show that a single low dose of lentiviral-transduced DC(HER2/neu) could significantly elevate serum anti-neu antibody level, stimulate the proliferation of CD4 and CD8 T lymphocytes and interferon-gamma secretion, induce a long lasting preventive effect against HER2/neu-overexpressing tumors and significantly suppress the growth of established HER2/neu-overexpressing tumors. CONCLUSIONS: The present study demonstrates that a single low dose of DCs modified with rLV containing a truncated neu oncogene can achieve a strong and long lasting effect on neu-overexpressing tumors, suggesting the possible clinical application of this strategy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Células Dendríticas
/
Lentivirus
/
Receptor ErbB-2
/
Proteínas Mutantes
/
Neoplasias
Limite:
Animals
Idioma:
En
Revista:
J Gene Med
Assunto da revista:
BIOLOGIA MOLECULAR
/
GENETICA MEDICA
Ano de publicação:
2010
Tipo de documento:
Article
País de afiliação:
China